Immunology News and Research

Latest Immunology News and Research

Patients with H1N1 flu die due to over-reactive immune response: Research

On November 19, Jason Martin returned to the Medical Intensive Care Unit at Vanderbilt University Medical Center for the first time since he nearly died there during last year's H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance worker - a 30-year-old, father of three young children - broke down and hugged some of the nurses he recognized.

6 Dec 2010

IDRI receives $790,200 BARDA grant to develop pandemic flu vaccine

The Infectious Disease Research Institute (IDRI) today announced it has received a $790,200 grant from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services. The grant enables technology transfer between IDRI and the Cantacuzino National Institute of Research and Development for Microbiology and Immunology (Bucharest, Romania), with the goal of producing a pandemic flu vaccine.

4 Dec 2010

BRI enters 3-year partnership with Roche to develop human immunology programs

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

4 Dec 2010

Mothers exposure to farm animals and cats during pregnancy lowers risk of atopic dermatitis in children

Children whose mothers are exposed to farm animals and cats are better protected against atopic dermatitis and are less likely to develop this painful inflammation of the skin in their first two years of life. A group of researchers from the University of Zurich and other universities have published evidence supporting this theory in the Journal of Allergy & Clinical Immunology.

3 Dec 2010

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that preliminary results from its cancer stem cell program, targeting the CD47 protein, will be reported in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida, December 4-7, 2010.

2 Dec 2010

ROCHE, Baylor Research Institute partner in human immunology research

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced today that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

2 Dec 2010

ASH honors Sen. Sherrod Brown and Erik Fatemi

The American Society of Hematology (ASH) will honor Senator Sherrod Brown (D-OH) with the 2010 ASH Award for Public Service and Erik Fatemi, Majority Clerk for the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS), with the Award for Outstanding Service in recognition of their dedication to championing health care and research issues. These awards will be officially announced at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando, FL.

2 Dec 2010

Booster dose needed to protect preterm infants against invasive pneumococcal disease

A new study suggests that preterm infants may not be fully protected against invasitve pneumococcal disease under the current United Kingdom immunization schedule. The findings are reported in the November issue of the journal Clinical and Vaccine Immunology.

2 Dec 2010

Shire reports topline results from FAST-3 Firazyr Phase III trials for acute attacks of hereditary angioedema

Shire plc, the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE).

2 Dec 2010

ASH to host annual meeting for blood disorders at Orange Convention Center

The American Society of Hematology (ASH) will host its 52nd annual meeting at the Orange County Convention Center in Orlando, FL, December 4-7. More than 20,000 attendees are expected for this event, which will highlight emerging research trends in the diagnosis, treatment, and understanding of blood disorders.

1 Dec 2010

Penicillamine challenge ineffective for detecting Wilson's disease in asymptomatic children

An Italian research team confirmed that the scoring system for Wilson's disease (WD) provides good diagnostic accuracy with 93% positive and 92% negative predictive values, respectively in children with mild liver disease. In asymptomatic children, a urinary copper excretion above 40 μg/24 hours was suggestive of WD, however the penicillamine challenge test (PCT) did not provide an accurate diagnosis in this patient subset.

1 Dec 2010

PepTcell changes name to SEEK

PepTcell, a leading UK privately-owned drug-discovery group, today announced it is changing its name to SEEK.

1 Dec 2010

Scripps Research Institute enters agreement with Aileron Therapeutics

The Scripps Research Institute and Aileron Therapeutics today announced that they have entered into an agreement that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide technology.

1 Dec 2010

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

The Kenneth Rainin Foundation announced today its 2011 Innovator Awards Program for Inflammatory Bowel Disease. The Program, now in its second year, is designed to accelerate the pace of discovery in IBD research.

30 Nov 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

A team of scientists from The Scripps Research Institute have uncovered a previously unknown regulatory mechanism in the body's response to eliminate pathogens, such as bacteria and viruses. The findings challenge a long-held dogma in the field of immunology and have potential implications for far-ranging topics from how vaccines should be administered to the origin of autoimmunity.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

New strategy to prevent memory deficits in mouse model with AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) in San Francisco have discovered a new strategy to prevent memory deficits in a mouse model of Alzheimer's disease (AD).

28 Nov 2010

Humanitarian benefits of rapid cholera vaccines deployment to at risk areas could be enormous

In the wake of devastating cholera outbreaks in refugee camps in earthquake-wracked Haiti, a group of leading experts from Harvard Medical School, George Washington University, and the International Vaccine Institute (IVI) have urged the United States to create an emergency stockpile of cholera vaccines for future humanitarian use.

25 Nov 2010

How HIV kills CD4 T cells

Researchers appear to have an explanation for a longstanding question in HIV biology: how it is that the virus kills so many CD4 T cells, despite the fact that most of them appear to be "bystander" cells that are themselves not productively infected. That loss of CD4 T cells marks the progression from HIV infection to full-blown AIDS, explain the researchers who report their findings in studies of human tonsils and spleens in the November 24th issue of Cell, a Cell Press publication.

25 Nov 2010

Immunology News and Research

Latest Immunology News and Research

Patients with H1N1 flu die due to over-reactive immune response: Research

IDRI receives $790,200 BARDA grant to develop pandemic flu vaccine

BRI enters 3-year partnership with Roche to develop human immunology programs

Mothers exposure to farm animals and cats during pregnancy lowers risk of atopic dermatitis in children

Trillium presents results from cancer stem cell program at ASH Annual Meeting

ROCHE, Baylor Research Institute partner in human immunology research

ASH honors Sen. Sherrod Brown and Erik Fatemi

Booster dose needed to protect preterm infants against invasive pneumococcal disease

Shire reports topline results from FAST-3 Firazyr Phase III trials for acute attacks of hereditary angioedema

ASH to host annual meeting for blood disorders at Orange Convention Center

Penicillamine challenge ineffective for detecting Wilson's disease in asymptomatic children

PepTcell changes name to SEEK

Scripps Research Institute enters agreement with Aileron Therapeutics

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

New strategy to prevent memory deficits in mouse model with AD

Humanitarian benefits of rapid cholera vaccines deployment to at risk areas could be enormous

How HIV kills CD4 T cells

Immunology eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology